中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

58 records (took 0.054 seconds)

    COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS
    1.
    发明申请
    COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS 审中-公开
    加重疾病的组合治疗

    公开(公告)号：WO2004105684A3

    公开(公告)日：2008-12-11

    申请号：PCT/US2004015346

    申请日：2004-05-13

    Applicant: INTERMUNE INC ,  BLATT LAWRENCE M ,  SEIWERT SCOTT D ,  OZES OSMAN N

    Inventor： BLATT LAWRENCE M ,  SEIWERT SCOTT D ,  OZES OSMAN N

    IPC: A61K38/00 ,  A61K20060101 ,  A61K31/00 ,  C07K14/00

    CPC classification number: A61K38/212 ,  A61K31/573 ,  A61K38/217 ,  A61K45/06 ,  A61K2300/00

    Abstract: The present invention provides methods of treating proliferative disorders, including angiogenesis-mediated disorders, cancer, and fibrotic disorders. In some embodiments, the methods involve administering a Type II interferon receptor agonist and a Type I interferon receptor agonist. In other embodiments, the methods involve administering a Type II interferon receptor agonist, a stress-activated protein kinase (SAPK) inhibitor, and a third therapeutic agent. In other embodiments, the methods involve administering a Type II interferon receptor agonist and a vascular endothelial growth factor (VEGF) antagonist. In other embodiments, the methods involve administering a VEGF antagonist and a SAPK inhibitor. The present invention further provides methods of treating fibrotic disorders. In some embodiments, the methods involve administering a Type I interferon receptor agonist, a Type II interferon receptor agonist; and a tumor necrosis factor (TNF) antagonist. In other embodiments, the methods involve administering a Type II interferon receptor agonist and a TNF antagonist. In other embodiments, the methods involve administering pirfenidone or a pirfenidone analog and a TNF antagonist. In other embodiments, the methods involve administering a Type II interferon receptor agonist and a transformining growth factor-beta (TGF-ß) antagonist. In other embodiments, the methods involve administering a SAPK inhibitor alone or in combination with a Type II interferon receptor agonist. In other embodiments, the methods involve administering N-acetyl cysteine (NAC) and a SAPK inhibitor. In other embodiments, the methods involve administering NAC and a Type II interferon receptor agonist.

    Abstract translation: 本发明提供了治疗增殖性疾病，包括血管发生介导的病症，癌症和纤维化病症的方法。 在一些实施方案中，所述方法包括施用II型干扰素受体激动剂和I型干扰素受体激动剂。 在其它实施方案中，所述方法包括施用II型干扰素受体激动剂，应激激活蛋白激酶（SAPK）抑制剂和第三治疗剂。 在其它实施方案中，所述方法包括施用II型干扰素受体激动剂和血管内皮生长因子（VEGF）拮抗剂。 在其它实施方案中，所述方法包括施用VEGF拮抗剂和SAPK抑制剂。 本发明还提供治疗纤维化疾病的方法。 在一些实施方案中，所述方法包括施用I型干扰素受体激动剂，II型干扰素受体激动剂; 和肿瘤坏死因子（TNF）拮抗剂。 在其它实施方案中，所述方法包括施用II型干扰素受体激动剂和TNF拮抗剂。 在其它实施方案中，所述方法包括施用吡非尼酮或吡非尼酮类似物和TNF拮抗剂。 在其它实施方案中，所述方法包括施用II型干扰素受体激动剂和变应性生长因子-β（TGF-β）拮抗剂。 在其它实施方案中，所述方法包括单独或与II型干扰素受体激动剂组合施用SAPK抑制剂。 在其它实施方案中，所述方法包括给予N-乙酰半胱氨酸（NAC）和SAPK抑制剂。 在其它实施方案中，所述方法包括施用NAC和II型干扰素受体激动剂。

    METHODS FOR TREATING HCV INFECTION
    2.
    发明申请
    METHODS FOR TREATING HCV INFECTION 审中-公开
    治疗HCV感染的方法

    公开(公告)号：WO2006016930A2

    公开(公告)日：2006-02-16

    申请号：PCT/US2005/016927

    申请日：2005-05-13

    Applicant: INTERMUNE, INC. ,  BLATT, Lawrence M.

    Inventor： BLATT, Lawrence M.

    IPC: A61K38/12

    CPC classification number: A61K38/217 ,  A61K2300/00

    Abstract: The present invention provides methods of treating hepatitis C virus (HCV) infection; methods of reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from HCV infection. The methods generally involve administering to the individual a Type II interferon receptor agonist alone or in combination with a direct antiviral drug.

    Abstract translation: 本发明提供治疗丙型肝炎病毒（HCV）感染的方法; 减少与HCV和肝硬化相关并发症发生率的方法; 以及在患有HCV感染的患者中减少病毒载量或减少病毒清除时间或减少临床结果的发病率或死亡率的方法。 所述方法通常包括单独给予个体II型干扰素受体激动剂或与直接抗病毒药物组合。

    COMBINATION THERAPY FOR TREATING HEPATITIS C VIRUS INFECTION
    5.
    发明申请
    COMBINATION THERAPY FOR TREATING HEPATITIS C VIRUS INFECTION 审中-公开
    治疗乙型肝炎病毒感染的组合疗法

    公开(公告)号：WO2005067454A2

    公开(公告)日：2005-07-28

    申请号：PCT/US2004/033959

    申请日：2004-10-13

    Applicant: INTERMUNE, INC. ,  BLATT, Lawrence, M.

    Inventor： BLATT, Lawrence, M.

    CPC classification number: A61K45/06 ,  A61K38/212 ,  A61K2300/00

    Abstract: The present invention provides methods of treating hepatitis C virus (HCV) infection; methods of reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from HCV infection. The methods generally involve administering to the individual i) a Type I interferon receptor agonist or a Type III interferon receptor agonist; ii) an immunomodulatory agent; and iii) an inhibitor of an HCV enzyme.

    Abstract translation: 本发明提供治疗丙型肝炎病毒（HCV）感染的方法; 减少与HCV和肝硬化相关并发症发生率的方法; 以及在患有HCV感染的患者中减少病毒载量或减少病毒清除时间或减少临床结果的发病率或死亡率的方法。 所述方法通常涉及给予个体i）I型干扰素受体激动剂或III型干扰素受体激动剂; ii）免疫调节剂; 和iii）HCV酶的抑制剂。

    METHOD OF TREATING ALCOHOLIC LIVER DISEASE
    6.
    发明申请
    METHOD OF TREATING ALCOHOLIC LIVER DISEASE 审中-公开
    治疗酒精性肝病的方法

    公开(公告)号：WO2005039598A1

    公开(公告)日：2005-05-06

    申请号：PCT/US2004/035139

    申请日：2004-10-21

    Applicant: INTERMUNE, INC. ,  BLATT, Lawrence M.

    Inventor： BLATT, Lawrence M.

    IPC: A61K31/70

    CPC classification number: A61K45/06 ,  A61K31/70 ,  A61K38/212 ,  A61K2300/00

    Abstract: The present invention provides a method of treating alcoholic hepatitis, the method involving administering to an individual in need thereof an effective amount of pirfenidone or a pirfenidone analog in monotherapy or in combination therapy. The invention further provides a method of treating alcoholic liver disease, the method involving administering to an individual in need thereof an effective amount of pirfenidone or a pirfenidone analog in combination therapy with a second therapeutic agent other than IFN-γ. The invention further provides a method of treating alcoholic liver disease, the method involving administering to an individual in need thereof an effective amount of pirfenidone or a pirfenidone analog, a Type II interferon receptor agonist, and a side effect management agent. The invention further provides a method of treating alcoholic liver disease, the method involving administering to an individual in need thereof an effective amount of a TNF-α antagonist, which therapy further includes administration of an effective amount of a Type II interferon receptor agonist, and/or pirfenidone or a pirfenidone analog.

    Abstract translation: 本发明提供一种治疗酒精性肝炎的方法，所述方法包括在单一疗法或联合治疗中向有需要的个体施用有效量的吡非尼酮或吡非尼酮类似物。 本发明还提供了一种治疗酒精性肝病的方法，所述方法包括向有需要的个体施用有效量的吡非尼酮或吡非尼酮类似物，其与除了IFN-γ以外的第二治疗剂组合治疗。 本发明还提供一种治疗酒精性肝病的方法，所述方法包括向有需要的个体施用有效量的吡非尼酮或吡非尼酮类似物，II型干扰素受体激动剂和副作用管理剂。 本发明还提供一种治疗酒精性肝病的方法，所述方法涉及向有需要的个体施用有效量的TNF-α拮抗剂，所述治疗还包括施用有效量的II型干扰素受体激动剂，以及 /或吡非尼酮或吡非尼酮类似物。

    COMPOSITIONS AND METHODS FOR TREATING POXVIRUS INFECTION
    8.
    发明申请
    COMPOSITIONS AND METHODS FOR TREATING POXVIRUS INFECTION 审中-公开
    治疗POXVIRUS感染的组合物和方法

    公开(公告)号：WO2004093901A1

    公开(公告)日：2004-11-04

    申请号：PCT/US2004/007509

    申请日：2004-03-11

    Applicant: INTERMUNE, INC. ,  MURPHY, Brian ,  BLATT, Lawrence M.

    Inventor： MURPHY, Brian ,  BLATT, Lawrence M.

    IPC: A61K38/20

    CPC classification number: A61K39/285 ,  A61K38/212 ,  A61K38/217 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/545 ,  A61K2039/55522 ,  A61K2300/00

    Abstract: The present invention provides methods of treating a poxvirus infection, e.g., a vaccinia virus or a variola virus infection; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from a poxviral infection. The present invention further provides methods of reducing the risk that an individual will develop a pathological poxvirus infection, such as a vaccinia virus infection or a variola virus infection, that has clinical sequelae. The methods generally involve administering a therapeutically effective amount of a Type I or Type III interferon receptor agonist and/or a Type II interferon receptor agonist for the treatment of a pox viral infection.

    Abstract translation: 本发明提供了治疗痘病毒感染的方法，例如痘苗病毒或天花病毒感染; 以及在患有痘病毒感染的患者中减少病毒载量或减少病毒清除时间或减少临床结果的发病率或死亡率的方法。 本发明进一步提供减少患有临床后遗症的病毒性痘病毒感染（例如痘苗病毒感染或天花病毒感染）的风险的方法。 所述方法通常包括给予治疗有效量的I型或III型干扰素受体激动剂和/或II型干扰素受体激动剂用于治疗痘病毒感染。

    INTERFERON DRUG THERAPY FOR THE TREATMENT OF VIRAL DISEASES AND LIVER FIBROSIS
    9.
    发明申请
    INTERFERON DRUG THERAPY FOR THE TREATMENT OF VIRAL DISEASES AND LIVER FIBROSIS 审中-公开
    用于治疗病毒和肝纤维化的干扰素治疗

    公开(公告)号：WO2004078207A1

    公开(公告)日：2004-09-16

    申请号：PCT/US2003/041369

    申请日：2003-12-23

    Applicant: INTERMUNE, INC. ,  BLATT, Lawrence, M. ,  HSU, Henry, H.

    Inventor： BLATT, Lawrence, M. ,  HSU, Henry, H.

    IPC: A61K39/29

    CPC classification number: A61K38/212 ,  A61K38/217 ,  A61K2300/00

    Abstract: The present invention provides methods of treating alphavirus infection; methods of treating hepatitis C virus (HCV) infection; methods of treating West Nile virus infection; methods of treating Dengue virus infection; methods of treating yellow fever virus infection; methods of reducing liver fibrosis; methods of increasing liver function in an individual suffering from liver fibrosis; methods of reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from viral infection. The methods generally involve administering a therapeutically effective amount of a Type I or Type III interferon receptor agonist and IFN-γ for the treatment of viral infection or liver fibrosis.

    Abstract translation: 本发明提供了治疗甲病毒感染的方法; 治疗丙型肝炎病毒（HCV）感染的方法; 治疗西尼罗病毒感染的方法; 登革热病毒感染方法 治疗黄热病毒感染的方法 减少肝纤维化的方法 增加肝纤维化患者肝功能的方法; 减少与HCV和肝硬化相关并发症发生率的方法; 以及在患有病毒感染的患者中减少病毒载量或减少病毒清除时间或减少临床结果的发病率或死亡率的方法。 所述方法通常涉及给予治疗有效量的I型或III型干扰素受体激动剂和IFN-γ用于治疗病毒感染或肝纤维化。

Patent Agency Ranking